Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer : the Europe IRIS study
Aim: To report the Europe Ibrance Real World Insights study findings. Methods: Physicians abstracted demographic/clinical characteristics, treatment and outcomes data for women with HR+/HER2- locally advanced breast cancer (ABC) or metastatic breast cancer (MBC) receiving palbociclib + aromatase inhibitor (AI) or palbociclib + fulvestrant. Kaplan-Meier analysis estimated progression-free rates (PFRs) and survival rates (SRs). Results: 238 physicians abstracted data for 1723 patients. For patients (>90%) initiating at 125 mg/day, dose was reduced in 18.9% of palbociclib + AI and 12.3% of palbociclib + fulvestrant patients. At 12 months, PFR for palbociclib + AI was 88.1%, and SR was 97.3%; PFR for palbociclib + fulvestrant was 79.8%, and SR was 97.5%. Conclusion: Low dose-reduction rates and favorable PFRs and SRs suggest that palbociclib + AI/fulvestrant is well tolerated and effective for HR+/HER2- ABC/MBC in real-world clinical practice.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
---|---|
Enthalten in: |
Future oncology (London, England) - 18(2022), 3 vom: 17. Jan., Seite 349-362 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Mycock, Katie [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 28.02.2022 Date Revised 28.02.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.2217/fon-2021-0716 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM333795113 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM333795113 | ||
003 | DE-627 | ||
005 | 20231225222400.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2217/fon-2021-0716 |2 doi | |
028 | 5 | 2 | |a pubmed24n1112.xml |
035 | |a (DE-627)NLM333795113 | ||
035 | |a (NLM)34842454 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Mycock, Katie |e verfasserin |4 aut | |
245 | 1 | 0 | |a Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer |b the Europe IRIS study |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 28.02.2022 | ||
500 | |a Date Revised 28.02.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Aim: To report the Europe Ibrance Real World Insights study findings. Methods: Physicians abstracted demographic/clinical characteristics, treatment and outcomes data for women with HR+/HER2- locally advanced breast cancer (ABC) or metastatic breast cancer (MBC) receiving palbociclib + aromatase inhibitor (AI) or palbociclib + fulvestrant. Kaplan-Meier analysis estimated progression-free rates (PFRs) and survival rates (SRs). Results: 238 physicians abstracted data for 1723 patients. For patients (>90%) initiating at 125 mg/day, dose was reduced in 18.9% of palbociclib + AI and 12.3% of palbociclib + fulvestrant patients. At 12 months, PFR for palbociclib + AI was 88.1%, and SR was 97.3%; PFR for palbociclib + fulvestrant was 79.8%, and SR was 97.5%. Conclusion: Low dose-reduction rates and favorable PFRs and SRs suggest that palbociclib + AI/fulvestrant is well tolerated and effective for HR+/HER2- ABC/MBC in real-world clinical practice | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Observational Study | |
650 | 4 | |a Europe | |
650 | 4 | |a medical chart review | |
650 | 4 | |a metastatic breast cancer | |
650 | 4 | |a palbociclib | |
650 | 4 | |a real world | |
650 | 4 | |a retrospective | |
650 | 7 | |a Aromatase Inhibitors |2 NLM | |
650 | 7 | |a Piperazines |2 NLM | |
650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
650 | 7 | |a Pyridines |2 NLM | |
650 | 7 | |a Receptors, Estrogen |2 NLM | |
650 | 7 | |a Receptors, Progesterone |2 NLM | |
650 | 7 | |a Fulvestrant |2 NLM | |
650 | 7 | |a 22X328QOC4 |2 NLM | |
650 | 7 | |a ERBB2 protein, human |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
650 | 7 | |a palbociclib |2 NLM | |
650 | 7 | |a G9ZF61LE7G |2 NLM | |
700 | 1 | |a Zhan, Lin |e verfasserin |4 aut | |
700 | 1 | |a Hart, Kieran |e verfasserin |4 aut | |
700 | 1 | |a Taylor-Stokes, Gavin |e verfasserin |4 aut | |
700 | 1 | |a Milligan, Gary |e verfasserin |4 aut | |
700 | 1 | |a Atkinson, Christian |e verfasserin |4 aut | |
700 | 1 | |a Mitra, Debanjali |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Future oncology (London, England) |d 2005 |g 18(2022), 3 vom: 17. Jan., Seite 349-362 |w (DE-627)NLM161450725 |x 1744-8301 |7 nnns |
773 | 1 | 8 | |g volume:18 |g year:2022 |g number:3 |g day:17 |g month:01 |g pages:349-362 |
856 | 4 | 0 | |u http://dx.doi.org/10.2217/fon-2021-0716 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 18 |j 2022 |e 3 |b 17 |c 01 |h 349-362 |